These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 36107574

  • 1. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
    Seo JH, Lim T, Ham A, Kim YA, Lee M.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30456. PubMed ID: 36107574
    [Abstract] [Full Text] [Related]

  • 2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Sep 02; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 3. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
    Mae S, Kuriyama A, Tachibana H.
    J Emerg Med; 2021 Mar 02; 60(3):342-344. PubMed ID: 33097350
    [Abstract] [Full Text] [Related]

  • 4. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug 02; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 5. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.
    Yabuki S, Hirai H, Moriya C, Kusano Y, Hasegawa T.
    Front Endocrinol (Lausanne); 2024 Aug 02; 15():1407192. PubMed ID: 38841300
    [Abstract] [Full Text] [Related]

  • 6. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
    Goff CB, Plaxe SC, White W, Dasanu CA.
    J Oncol Pharm Pract; 2023 Jul 02; 29(5):1259-1263. PubMed ID: 36734125
    [Abstract] [Full Text] [Related]

  • 7. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
    Ning P, Liu S, Cao H.
    J Med Case Rep; 2024 Jan 22; 18(1):51. PubMed ID: 38247005
    [Abstract] [Full Text] [Related]

  • 8. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
    Iesaka H, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Abe T, Shinohara N, Atsumi T.
    Medicine (Baltimore); 2023 Dec 22; 102(51):e36664. PubMed ID: 38134115
    [Abstract] [Full Text] [Related]

  • 9. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
    Ishiguro A, Ogata D, Ohashi K, Hiki K, Yamakawa K, Jinnai S, Tsutsui K, Takahashi A, Namikawa K, Yamazaki N.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30398. PubMed ID: 36107581
    [Abstract] [Full Text] [Related]

  • 10. Pregnancy and delivery in an advanced cancer survivor with immune checkpoint inhibitor-induced type 1 diabetes: a case report.
    Sugai K, Miwa T, Kojima J, Ueda Y, Tsukahara K, Nishi H, Suzuki R.
    Endocrine; 2024 Aug 02; 85(2):593-597. PubMed ID: 38502365
    [Abstract] [Full Text] [Related]

  • 11. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2018 Jan 02; 244(1):33-40. PubMed ID: 29343652
    [Abstract] [Full Text] [Related]

  • 12. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
    Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S.
    Front Immunol; 2023 Jan 02; 14():1229823. PubMed ID: 37671166
    [Abstract] [Full Text] [Related]

  • 13. Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.
    Fujiwara M, Shimizu M, Okano T, Maejima Y, Shimomura K.
    Front Public Health; 2023 Jan 02; 11():1264056. PubMed ID: 38106883
    [Abstract] [Full Text] [Related]

  • 14. Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.
    Daetwyler E, Zippelius A, Danioth S, Donath MY, Gut L.
    Front Immunol; 2023 Jan 02; 14():1248919. PubMed ID: 37965350
    [Abstract] [Full Text] [Related]

  • 15. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report.
    Abe K, Ishikawa Y, Fujiwara M, Yukawa H, Yanagihara T, Takei S, Arioka H, Kita Y.
    Medicine (Baltimore); 2022 Jan 14; 101(2):e28428. PubMed ID: 35029182
    [Abstract] [Full Text] [Related]

  • 16. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
    Matsuura N, Koh G, Konishi C, Minamino S, Takahara Y, Harada H, Kodama K, Emoto M.
    Cancer Immunol Immunother; 2018 Sep 14; 67(9):1417-1424. PubMed ID: 29995236
    [Abstract] [Full Text] [Related]

  • 17. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.
    Sakaguchi C, Ashida K, Yano S, Ohe K, Wada N, Hasuzawa N, Matsuda Y, Sakamoto S, Sakamoto R, Uchi H, Furue M, Nomura M, Ogawa Y.
    Curr Oncol; 2019 Feb 14; 26(1):e115-e118. PubMed ID: 30853818
    [Abstract] [Full Text] [Related]

  • 18. New-onset insulin-dependent diabetes due to nivolumab.
    Zaied AA, Akturk HK, Joseph RW, Lee AS.
    Endocrinol Diabetes Metab Case Rep; 2018 Feb 14; 2018():. PubMed ID: 29623210
    [Abstract] [Full Text] [Related]

  • 19. Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases.
    Luo J, Feng J, Liu C, Yang Z, Zhan D, Wu Y, Pan L, Zhang L.
    J Int Med Res; 2022 Sep 14; 50(9):3000605221121940. PubMed ID: 36171723
    [Abstract] [Full Text] [Related]

  • 20. Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.
    Hatakeyama Y, Ohnishi H, Suda K, Okamura K, Shimada T, Yoshimura S.
    J Oncol Pharm Pract; 2019 Dec 14; 25(8):2023-2026. PubMed ID: 30526346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.